Cellectar Biosciences, Inc.
CLRB
$2.37
-$0.05-1.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -51.00% | -52.35% | -55.22% | -35.26% | 13.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.90% | -51.55% | -55.62% | -41.77% | -19.21% |
| Operating Income | 38.90% | 51.55% | 55.62% | 41.77% | 19.21% |
| Income Before Tax | 23.04% | 14.86% | 51.05% | 62.55% | 45.30% |
| Income Tax Expenses | -- | -- | -- | 210.00% | 210.00% |
| Earnings from Continuing Operations | 23.21% | 15.09% | 51.12% | 62.38% | 45.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.21% | 15.09% | 51.12% | 62.38% | 45.11% |
| EBIT | 38.90% | 51.55% | 55.62% | 41.77% | 19.21% |
| EBITDA | 39.00% | 51.74% | 55.78% | 41.89% | 19.28% |
| EPS Basic | 77.65% | 58.67% | 74.61% | 80.37% | 77.21% |
| Normalized Basic EPS | 77.60% | 58.56% | 74.58% | 80.50% | 77.29% |
| EPS Diluted | 78.60% | 68.48% | 77.65% | 82.20% | 77.35% |
| Normalized Diluted EPS | 77.46% | 58.18% | 74.47% | 80.44% | 77.43% |
| Average Basic Shares Outstanding | 305.58% | 141.20% | 113.37% | 93.34% | 91.87% |
| Average Diluted Shares Outstanding | 304.52% | 138.16% | 110.37% | 90.02% | 89.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |